Abstract
Lorlatinib is a selective, potent, brain-penetrant, third-generation tyrosine kinase inhibitor (TKI) that targets ALK and ROS1. In a global Phase II trial, lorlatinib showed substantial overall and intracranial activity in patients with ALK- or ROS1-positive advanced non-small cell lung cancer (NSCLC). Here we report the efficacy and biomarkers of lorlatinib from the Asian subgroup analysis of this trial.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
